Literature DB >> 1280451

Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin.

D G Hoyt1, J S Lazo.   

Abstract

The DNA-cleaving, antitumor antibiotic bleomycin (BLM) causes pulmonary fibrosis, but the essential early events initiating the fibrotic state have not been well characterized. Thus, we have directly examined BLM-mediated pulmonary cell injury by monitoring lactate dehydrogenase (LDH) release and nuclear poly(ADP-ribose) polymerase (PAP) activity, which is stimulated by DNA breakage, using lung slices isolated from BLM-sensitive (C57B1/6) and BLM-resistant (BALB/c) mice. Lung slices were incubated continuously with or without the PAP inhibitor, 3-aminobenzamide (3-AB), and exposed to BLM for 45 min. LDH release from C57B1/6 lung slices increased 2-fold by 8.5 h after treatment with BLM. In contrast, BLM failed to enhance cumulative LDH release by BALB/c mouse lung slices. Co-incubation of C57B1/6 lung slices with 3-AB prevented BLM-induced LDH release. Nuclear PAP was activated 3- to 4-fold 1.25 h after exposure of C57B1/6 lung slices to BLM but returned to control levels by 3.75 h. Nuclear PAP was only marginally affected at these times in BALB/c lung slices. Co-incubation of C57B1/6 slices with 3-AB prevented the early increases in PAP activity. These results demonstrate that murine strain sensitivity to acute cell injury and early PAP activation by BLM in lung slices parallels the in vivo sensitivity of lungs. In addition, 3-AB suppresses PAP activation and acute cell injury in lung slices. Differential activation of PAP appears to govern murine strain variation in response to BLM and is consistent with the hypothesis that activation of PAP participates in acute pneumocyte injury, initiating the process of BLM-induced fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280451     DOI: 10.1165/ajrcmb/7.6.645

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

Review 1.  The molecular basis of asbestos induced lung injury.

Authors:  D W Kamp; S A Weitzman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis.

Authors:  Min Huang; Sherven Sharma; Li X Zhu; Michael P Keane; Jie Luo; Ling Zhang; Marie D Burdick; Ying Q Lin; Mariam Dohadwala; Brian Gardner; Raj K Batra; Robert M Strieter; Steven M Dubinett
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

3.  The role of p53 in bleomycin-induced DNA damage in the lung. A comparative study with the small intestine.

Authors:  K Okudela; T Ito; H Mitsui; H Hayashi; N Udaka; M Kanisawa; H Kitamura
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

4.  Soluble TNF mediates the transition from pulmonary inflammation to fibrosis.

Authors:  Nikos Oikonomou; Vaggelis Harokopos; Jonathan Zalevsky; Christos Valavanis; Anastasia Kotanidou; David E Szymkowski; George Kollias; Vassilis Aidinis
Journal:  PLoS One       Date:  2006-12-27       Impact factor: 3.240

5.  HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway.

Authors:  Laura Lucarini; Mariaconcetta Durante; Cecilia Lanzi; Alessandro Pini; Giulia Boccalini; Laura Calosi; Flavio Moroni; Emanuela Masini; Guido Mannaioni
Journal:  J Cell Mol Med       Date:  2016-10-04       Impact factor: 5.310

Review 6.  Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

Authors:  Nicola Curtin; Krisztián Bányai; James Thaventhiran; John Le Quesne; Zsuzsanna Helyes; Péter Bai
Journal:  Br J Pharmacol       Date:  2020-07-05       Impact factor: 8.739

7.  The role of mouse strain differences in the susceptibility to fibrosis: a systematic review.

Authors:  Louise Walkin; Sarah E Herrick; Angela Summers; Paul E Brenchley; Catherine M Hoff; Ron Korstanje; Peter J Margetts
Journal:  Fibrogenesis Tissue Repair       Date:  2013-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.